MIL-62 is under clinical development by Beijing Mabworks Biotech and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase II drugs for Systemic Lupus Erythematosus have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MIL-62’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MIL-62 overview

MIL-62 is under development for the treatment of chronic lymphocytic leukemia, relapsed/refractory and previously untreated follicular lymphoma, relapsed/refractory and newly diagnosed diffuse large B cell lymphoma and intranodal marginal zone lymphoma, systemic lupus erythematosus (SLE), extranodal marginal zone lymphoma, splenic marginal zone lymphoma, lupus nephritis, primary membranous nephropathy, myasthenia gravis, neuromyelitis optica, relapsed/refractory B-cell non-Hodgkin lymphoma. The drug candidate is administered by intravenous drip route and acts by targeting cells expressing B-lymphocyte antigen CD20. It is a biobetter.

Beijing Mabworks Biotech overview

Beijing Mabworks Biotech (Beijing Mabworks Biotech Co) that develops and designs new prototype humanized and fully human monoclonal antibodies, oncology drugs, and other products. The company is headquartered in Beijing, Beijing, China.

For a complete picture of MIL-62’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.